MFNG (MFNG) (Middle Region) Peptide
MFNG
Reactivity: Human, Mouse
Host: Synthetic
BP, WB
Quick Overview for MFNG (MFNG) (Middle Region) Peptide (ABIN980024)
Target
Manic Fringe (MFNG)
(MFNG)
Origin
Human, Mouse
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Sequence
- CKLGGRLQPS PLFHSHLETL QLLGAAQLPE QVTLSYGVFE GKLNVIKLPG
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-Mfng Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- Manic Fringe (MFNG) (MFNG)
-
Background
-
Glycosyltransferase is involved in the elongation of O-linked ligands to activate Notch signaling. Mfng possesses fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity.
Alias Symbols: AW546563
Protein Size: 321 -
Molecular Weight
- 36 kDa
-
Gene ID
- 17305
-
NCBI Accession
- NM_008595, NP_032621
-
UniProt
- O09008
Target
-
You are here:
